Commercial, Medicare Part D (MPD) and Medicaid Formulary Decisions

Transcription

1 Interoffice Memo To: All MAPMG Providers From: Sheireen Huang, PharmD Regional Clinical Pharmacy Services Manager Pharmacy Co-Chair, Regional P&T Committee CC: Pharmacy Department Date: March 6, 2015 Re: March Pharmacy and Therapeutics Committee Formulary Decisions Carol Forster, MD Physician Director, Pharmacy & Therapeutics/Medication Safety Physician Co-Chair, Regional P&T Committee The chart below outlines KPMAS Commercial, Maryland HealthChoice, Virginia Medicaid and Medicare Part D (MPD) formulary decisions from the March 2015 KPMAS Regional Pharmacy & Therapeutics Committee meeting. Detailed evidence-based drug monographs used when evaluating these products are available by request. In addition, please see the attached for summary of tips on how to find formulary information online and the formulary review process. Please feel free to contact Sheireen Huang, PharmD and/or Carol Forster, MD via at [email protected] and/or [email protected] if there are any questions. Commercial, Medicare Part D (MPD) and Medicaid Formulary Decisions Trumenba (Meningococcal Group Trumenba is FDA-approved in individuals aged years for active B Vaccine) 0.5 ml injection immunization against invasive disease caused by Neisseria meningitidis serogroup B. Menactra and Menveo (for high risk patients) are the KP-preferred meningococcal vaccines. ADD Trumenba to the commercial, MD HealthChoice and VA Medicaid formularies; effective 3/2/2015. Vyvanse (lisdexamfetamine) 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg capsules Maintain on Tier 6 of the MPD formulary. Vyvanse does not offer any clinically significant benefits over the formulary preferred stimulant, Adderall XR, for treatment of attentiondeficit/hyperactivity disorder (ADHD) and should be reserved for those patients who have failed and/or are not candidates for Adderall XR. Although, Vyvanse was recently FDA-approved for the treatment of moderate to severe Binge Eating Disorder (BED), its comparative efficacy to current treatment options such as, selective serotonin reuptake inhibitors (SSRIs), is unknown. Reviewed and voted to REMOVE Vyvanse 20 mg, 30 mg 40 mg, 50 mg, 60 mg and 70 mg capsules from the commercial and VA Medicaid formularies; effective 5/5/2015. Reviewed and voted to NOT add Vyvanse 10 mg capsule to the commercial and VA Medicaid formularies. Vyvanse is carved out on the MD HealthChoice formulary. Maintain Vyvanse 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg on Tier 3; recommend to ADD Vyvanse 20 mg, 30 mg 40 mg, 50 mg, 60 mg, and 70 mg capsules to Tier 4 of the MPD formulary; effective 1/1/2016. Maintain Vyvanse 10 mg on Tier 4 of the MPD formulary.

2 Commercial, Medicare Part D (MPD) and Medicaid Formulary Decisions cont d Colchicine (generic Mitigare) Colchicine capsule is the KP-preferred generic colchicine product and 0.6 mg capsules is indicated for gout flare prophylaxis in adults. Colchicine capsule is an authorized generic (AG) of Mitigare. Reviewed and voted to ADD colchicine capsule to the commercial, MD HealthChoice and VA Medicaid formularies; effective 3/23/2015. ADD on Tier 3 of the MPD formulary; effective 4/7/2015. Colchicine (generic Colcrys) 0.6 mg tablets Azelastine (generic Astelin) 0.1% nasal spray Lovenox (enoxaparin) 300 mg/3 ml vial injection FIRST-Lansoprazole (lansoprazole) 3 mg/ml oral suspension Colchicine tablet is no longer the KP-preferred generic colchicine product. Reviewed and voted to REMOVE colchicine tablet from the commercial, MD HealthChoice and VA Medicaid formularies; effective 5/5/2015. Maintain on Tier 2 of the MPD formulary. Azelastine should be reserved for patients who do not respond or tolerate nasal corticosteroids and/or over-the-counter low-sedating oral antihistamines. Azelastine remains the most cost-effective intranasal antihistamine available and current prescribing restrictions has had little effect on utilization. Reviewed and voted to REMOVE prescribing restrictions to Allergy and ENT; maintain on commercial, MD HealthChoice and VA Medicaid formularies. Maintain on Tier 2 of the MPD formulary. Low dose Lovenox, 30 mg and 40 mg, are not available in graduated syringes and this may lead to medication errors in pediatric patients during dose administration. Lovenox 300 mg/3 ml in multi-dose vials, administered with an insulin syringe, will allow for accurate dose administration in the pediatric patients requiring doses of less than 50 mg. Reviewed and voted to ADD Lovenox 300 mg/3 ml to the commercial and VA Medicaid formularies; effective 4/7/2015. ADD to the MD HealthChoice formulary; effective 5/5/2015. Maintain on Tier 3 of the MPD formulary. FIRST-lansoprazole compounding kit is a lansoprazole oral suspension that should be limited to patients who are unable to use capsules, such as pediatric patients. Lansoproprazole is not the KPpreferred proton pump inhibitor (PPI). FIRST-lansoprazole contains benzyl alcohol; large amounts of benzyl alcohol ( 99 mg/kg/day) have been associated with a potentially fatal gasping syndrome in neonates. Reviewed and voted to NOT add FIRST-lansoprazole to the commercial, MD HealthChoice and VA Medicaid formularies. Maintain on Tier 4 of the MPD formulary. REMOVE extemporaneously compounded lansoprazole oral suspension from the KPMAS List of Standard Compounds; effective 5/5/2015.

3 Commercial, Medicare Part D (MPD) and Medicaid Formulary Decisions cont d First-Omeprazole (omeprazole) Extemporaneously prepared omeprazole suspension is prepared 2 mg/ml oral suspension using sodium bicarbonate which has had shortage issues. First-Omeprazole is a strawberry flavored omeprazole oral suspension with improved taste, tolerability, and efficiency of compounding. It is the preferred proton pump inhibitor (PPI) option for patients unable to swallow capsules. Reviewed and recommended to ADD First-Omeprazole to the commercial, MD HealthChoice and VA Medicaid formularies; pending MPD tier change. Recommend ADD to Tier 3 of the MPD formulary. REMOVE extemporaneously compounded omeprazole oral suspension from the KPMAS List of Standard Compounds; effective Omeprazole+SyrSpend SF Cherry Alka (omeprazole) 2 mg/ml oral suspension Compounded Enalapril 1 mg/ml oral suspension (enalapril maleate 20 mg tablets, Ora-Sweet/Ora- Plus mixture or cherry syrup) Compounded Isoniazid 10 mg/ml oral suspension (isoniazid 100 mg tablets, water, and sorbitol) 5/5/2015. Omeprazole+SyrSpend SF Cherry Alka is a commercially available formulation of omeprazole oral suspension. A more cost-effective omeprazole oral suspension, First-Omeprazole is available and preferred at KPMAS. Reviewed and voted to NOT add Omeprazole+SyrSpend SF Cherry Alka to the commercial, MD HealthChoice and VA Medicaid formularies. Maintain on Tier 4 of the MPD formulary. REMOVE extemporaneously compounded omeprazole oral suspension from the KPMAS List of Standard Compounds; effective 5/5/2015. KPMAS List of Standard Compounds Commercially formulated Epaned (enalapril) powder for 1 mg/ml oral solution is available in the same concentrations as the extemporaneous compound. Epaned is not on the commercial, MD HealthChoice and VA Medicaid formularies. Extemporaneous compounds are not recommended over the commercially available product. Reviewed and voted to REMOVE extemporaneously compounded enalapril oral suspension from the KPMAS List of Standard Compounds; effective 5/5/2015. Commercially formulated generic isoniazid 50 mg/5 ml syrup is available in the same concentrations as the extemporaneous compound. Generic isoniazid 50 mg/5 ml syrup is formulary. Extemporaneous compounds are not recommended over the commercially available product. Reviewed and voted to REMOVE extemporaneously compounded isoniazid oral suspension from the KPMAS List of Standard Compounds; effective 5/5/2015.

4 Compounded Carbamazepine 10 mg/ml oral suspension (carbamazepine 200 mg tablets, sterile water, and cherry syrup) Mercaptopurine 50 mg/ml oral suspension (mercaptopurine 50 mg tablets, sterile water, simple syrup and cherry syrup) KPMAS List of Standard Compounds cont d Commercially formulated carbamazepine 100 mg/5 ml oral suspension is available and on the formulary. The concentration of the commercially available product is sufficiently similar to the extemporaneous compound. Reviewed and voted to REMOVE extemporaneously compounded carbamazepine oral suspension from the KPMAS List of Standard Compounds; effective 5/5/2015. Commercially formulated Purixan (mercaptopurine) 20 mg/ml oral suspension is available. Purixan can eliminate the safety concerns of handling mercaptopurine, a cytotoxic agent, during compound preparation. Reviewed and voted to REMOVE extemporaneously compounded mercaptopurine oral suspension from the KPMAS List of Standard Compounds; effective 5/5/2015. At the February 2015 P&T meeting, recommended to ADD Purixan to the commercial, MD HealthChoice and VA Medicaid formularies; pending MPD change from Tier 4 to Tier 3. Commercial, Medicare Part D (MPD) and Medicaid Formulary Decisions cont d Anti-Infective Agents Anthelmintics Antibacterials Aminoglycosides Cephalosporins First Generation Cephalosporins Second Generation Cephalosporins Third Generation Cephalosporins Fourth Generation Cephalosporins Fifth Generation Cephalosporins Miscellaneous Beta Lactams Carbacephems Carbapenems Cephamycins Monobactams Chloramphenicol Class Reviews Reviewed and voted to REMOVE Azactam (aztreonam) 2 g injection from the commercial, MD HealthChoice, and VA Medicaid formularies; effective 5/5/2015. Maintain Azactam (aztreonam) 2 g injection on Tier 3 of the MPD formulary. Recommend to ADD Azactam (aztreonam) 2 g injection to Tier 4 of the MPD formulary; effective 1/1/2016. Reviewed and voted to ADD aztreonam (generic Azactam) 1 g and 2 g injection to the commercial and VA Medicaid formularies; effective 4/7/2015. ADD aztreonam (generic Azactam) 1 g and 2 g injection to the MD HealthChoice formulary; effective 5/5/2015. Maintain aztreonam (generic Azactam) 1 g and 2 g injection on Tier 2 of the MPD formulary.

5 Macrolides Erythromycins Ketolides Other macrolides Penicillins Natural Penicillins Aminopenicillins Commercial, Medicare Part D (MPD) and Medicaid Formulary Decisions cont d Penicillinase-resistant Extended-spectrum Quinolones Sulfonamides Tetracyclines Miscellaneous Antibacterials Aminocyclitols Bacitracins Class Reviews Azithromycin (generic Zithromax) 1 g oral pack is available on formulary. Reviewed and voted to REMOVE Zithromax (azithromycin) 1 g oral pack from the commercial, MD HealthChoice, and VA Medicaid formularies; effective 5/5/2015. Maintain Zithromax (azithromycin) 1 g oral pack on Tier 3 of the MPD formulary. Recommend to ADD Zithromax (azithromycin) 1 g to Tier 4 of the MPD formulary; effective 1/1/2016. Ampicillin and sulbactam (generic Unasyn) 1.5 g and 3 g injection is available on formulary. Reviewed and voted to REMOVE Unasyn (ampicillin and sulbactam) 1.5 g and 3 g injection from the commercial, MD HealthChoice, and VA Medicaid formularies effective 5/5/2015. Maintain Unasyn (ampicillin and sulbactam) 1.5 g and 3 g injection on Tier 4 of the MPD formulary. Cyclic Lipopeptides Glycopeptides Lincomycins Clindamycin (generic Cleocin) is continually used as a clinic administered medication in the Critical Decision Units (CDU) and Ambulatory Surgery Centers (ASC). Reviewed and voted to ADD clindamycin (generic Cleocin) 300 mg/2 ml, 600 mg/4 ml, 900 mg/6 ml injection to the commercial and VA Medicaid formularies; effective 4/7/2015. ADD clindamycin (generic Cleocin) 300 mg/2 ml, 600 mg/4 ml, 900 mg/6 ml injection to the MD HealthChoice formulary; effective 5/5/2015. Clindamycin (generic Cleocin) 9 gm/60 ml (150 mg/ml) and 9000 mg/60 ml has low utilization. Reviewed and voted to REMOVE clindamycin (generic Cleocin) 9 gm/60 ml (150 mg/ml) and 9000 mg/60 ml from the commercial, MD HealthChoice, and VA Medicaid formularies; effective 5/5/2015. Maintain clindamycin (generic Cleocin) on Tier 2 of the MPD formulary.

6 Oxazolidinone Commercial, Medicare Part D (MPD) and Medicaid Formulary Decisions cont d Polymyxins Rifamycins Streptogramins Antifungals Allylamines Azoles Echinocandins Polyenes Pyrimidines Miscellaneous Antifungals Antimycobacterials Antituberculosis Agents Miscellaneous Antimycobacterials Antivirals Adamantanes Antiretrovirals Interferons Monoclonal Antibodies Neuraminidase Inhibitors Nucleosides and Nucleotides HCV Protease Inhibitors Miscellaneous Antivirals Antiprotozoals Amebicides Antimalarials Miscellaneous Antiprotozoals Class Reviews Reviewed and voted to REMOVE Zyvox (linezolid) 2 mg/ml injection from the commercial, MD HealthChoice, and VA Medicaid formularies; effective 5/5/2015. Maintain Zyvox (linezolid) 2 mg/ml injection on Tier 5 of the MPD formulary. Reviewed and voted to ADD linezolid (generic Zyvox) 2 mg/ml injection to the commercial and VA Medicaid formularies; effective 4/7/2015. ADD linezolid (generic Zyvox) 2 mg/ml injection to the MD HealthChoice formulary; effective 5/5/2015. Maintain linezolid (generic Zyvox) injection on Tier 2 of the MPD formulary. Reviewed and voted to REMOVE Grifulvin V (griseofulvin) 500 mg tablets from the commercial, MD HealthChoice, and VA Medicaid formularies; effective 5/5/2015. Maintain Grifulvin V (griseofulvin) 500 mg tablets on Tier 4 of the MPD formulary. Reviewed and voted to ADD griseofulvin (generic Grifulvin V) 500 mg tablets to the commercial and VA Medicaid formularies; effective 4/7/2015. ADD griseofulvin (generic Grifulvin V) 500 mg tablets to the MD HealthChoice formulary; effective 5/5/2015. Maintain griseofulvin (generic Grifulvin V) on Tier 2 of the MPD formulary.

7 Commercial, Medicare Part D (MPD) and Medicaid Formulary Decisions cont d Urinary Anti-infectives Autonomic Drugs Parasympathomimetic Anticholinergic Agents Antimuscarinics/Antispasmodics Sympathomimetic (Adrenerigic) Agents Alpha Adrenergic Agonists Class Reviews Macrodantin (nitrofurantoin) 25 mg capsules have low utilization and is available as generic in other strengths. Reviewed and voted to REMOVE Macrodantin (nitrofurantoin) 25 mg capsules from the commercial, MD HealthChoice, and VA Medicaid formularies; effective 5/5/2015. Maintain Macrodantin (nitrofurantoin) 25 mg capsules on Tier 3 of the MPD formulary. Recommend to ADD Macrodantin (nitrofurantoin) 25 mg capsules to Tier 4 of the MPD formulary; effective 1/1/2016. Beta Adrenergic Agonists Non-selective Beta Adrenergic Agonists Selective Beta-1 Adrenergic Agonists Selective Beta-2 Adrenergic Agonists Dopamine and dobutamine injections are used in the pediatric and adult crash carts. Reviewed and voted to ADD dopamine 400 mg/250 ml injection to the commercial and VA Medicaid formularies; effective 4/7/2015. ADD dopamine 400 mg/250 ml injection to the MD HealthChoice formulary; effective 5/5/2015. Reviewed and voted to ADD dobutamine 500 mg/250 ml injection to the commercial and VA Medicaid formularies; effective 4/7/2015. ADD dobutamine 500 mg/250 ml injection to the MD HealthChoice formulary; effective 5/5/2015. Dopamine and dobutamine injections are exempt from the MPD formulary. ProAir (albuterol) multi-dose inhaler is available on formulary. Maintain Ventolin HFA (albuterol) 90 mcg/inhalation as nonformulary on the commercial, MD HealthChoice, and VA Medicaid formularies. Maintain Proventil HFA (albuterol) 90 mcg/inhalation as nonformulary on the commercial, MD HealthChoice, and VA Medicaid formularies. Maintain Ventolin HFA and Proventil HFA 90 mcg/inhalation on Tier 4 of the MPD formulary.

8 Commercial, Medicare Part D (MPD) and Medicaid Formulary Decisions cont d Alpha and Beta Adrenergic Agonists Sympatholyitc (Adrenergic Blocking) Agents Alpha-adrenergic Blocking Agents Non-selective Alpha-adrenergic Blocking Agents Alpha 1-selective Adrenergic Blocking Agents Skeletal Muscle Relaxants (SMRs) Centrally Acting Skeletal Muscle Relaxants Direct-acting Skeletal Muscle Relaxants GABA-derivative Skeletal Muscle Relaxants Neuromuscular Blocking Agents Miscellaneous Skeletal Muscle Relaxants Miscellaneous Autonomic Drugs Class Reviews Epinephrine (generic Adrenaclick) 0.15 mg and 0.3 mg auto-injector are available on formulary. Maintain Adrenaclick (epinephrine) 0.15 mg and 0.3 mg auto-injector as nonformulary on the commercial, MD HealthChoice, and VA Medicaid formularies. Maintain Auvi-Q (epinephrine) 0.3 mg auto-injector as nonformulary on the commercial, MD HealthChoice, and VA Medicaid formularies. Maintain Twinject (epinephrine) 0.15 mg and 0.3 mg auto-injector as nonformulary on the commercial, MD HealthChoice, and VA Medicaid formularies. Maintain Twinject 0.15 mg and 0.3 mg auto-injector on Tier 3 of the MPD formulary. Recommend to ADD Twinject 0.15 mg and 0.3 mg to Tier 4 of the MPD formulary; effective 1/1/2016. Maintain Adrenaclick and Auvi-Q 0.15 mg and 0.3 mg auto-injector on Tier 4 of the MPD formulary. Reviewed and voted to ADD dantrium (generic Revonto) 20 mg injection to the commercial and VA Medicaid formularies; effective 4/7/2015. ADD dantrium (generic Revonto) 20 mg injection to the MD HealthChoice formulary; effective 5/5/2015. Dantrium (generic Revonto) is exempt from the MPD formulary. Dantrolene (generic Dantrium) 50 mg capsule is the only strength of dantrolene not included on formulary that is currently being utilized. Reviewed and voted to ADD dantrolene (generic Dantrium) 50 mg capsules to the commercial and VA Medicaid formularies; effective 4/7/2015. ADD dantrolene (generic Dantrium) 50 mg capsule to the MD HealthChoice formulary; effective 5/5/2015. Maintain dantrolene 50 mg (generic Dantrium) capsules on Tier 2 of the MPD formulary.

9 Decongestants Symphathomimetic (Adrenergic) Agents Alpha-Adrenergic Agonists Alpha- and Beta- Adrenergic Agonists Nicotine Cessation Autonomic Drugs, Miscellaneous Azelastine (generic Astelin) 1% Nasal Spray Over-the-Counter (OTC) Class Reviews for Medicaid Reviewed and voted to ADD all generic OTC products and REMOVE all branded OTC products, if an equivalent generic OTC is available, from the VA Medicaid formulary; effective 5/5/2015. Decongestant OTC products are exempt from the MD HealthChoice Formulary. OTC products are exempt from the commercial and MPD formularies. Reviewed and voted to ADD all generic OTC products and REMOVE all branded OTC products, if an equivalent generic OTC is available, from the VA Medicaid formulary; effective 5/5/2015. Decongestant OTC products are exempt from the MD HealthChoice Formulary. OTC products are exempt from the commercial and MPD formularies. Reviewed and voted to ADD all generic OTC products and REMOVE all branded OTC products, if an equivalent generic OTC is available, from the VA Medicaid formulary; effective 5/5/2015. Decongestant OTC products are exempt from the MD HealthChoice Formulary. OTC products are exempt from the commercial and MPD formularies. Reviewed and voted to ADD all generic OTC products and REMOVE all branded OTC products, if an equivalent generic OTC is available, from the VA Medicaid formulary; effective 5/5/2015. Nicotine cessation products are carved out of MD HealthChoice Formulary. OTC products are exempt from the commercial and MPD formularies. Prescribing Recommendations Azelastine 1% (generic Astelin) is an intranasal second-generation antihistamine recommended in clinical guidelines as an adjunct therapy for management of allergic and non-allergic rhinitis. This guideline promotes the use of nasal corticosteroids and OTC lowsedating oral antihistamines as first-line agents in treating seasonal allergic rhinitis. Azelastine should be reserved for patients who do not respond or tolerate nasal corticosteroids and/or OTC low-sedating oral antihistamines. Reviewed and endorsed. Annual Review of Policies and Procedures POLICIES AND PROCEDURES This policy outlines expectations and requirements regarding the appropriate relationships between MAPMG providers and KPMAS Medical Sales Representatives health plan staff with pharmaceutical manufacturers. Reviewed and endorsed. Maryland HealthChoice and Virginia Medicaid Prior Authorizations Hepatitis C Therapy Prior Authorization The prior authorization form was updated to include: o Viekira Pak on the medication list o A new section reflecting Laboratory Results o A new section reflecting Treatment Plan o A new section reflecting Medical History and o A new section reflecting Prior Drug Utilization Reviewed and approved the revised prior authorization criteria for Harvoni, Olysio, Sovaldi, and Viekira Pak for Treatment of Hepatitis C.

10 Inter-regional MPD Pharmacy and Therapeutics (im-pact) Committee February 4th, 2015 meeting Drug Decisions Blincyto (blinatumomab) Protected Class. 35 mcg injection Confirmed Specialty Tier 5 status. Opdivo (nivolumab) 40 mg/4 ml, 100 mg/10 ml injection Lynparza (olaparib) 50 mg capsules Protected Class. Confirmed Specialty Tier 5 status. Confirmed Specialty Tier 5 status, Protected Class. Grastek (timothy grass pollen Retained on Non-Preferred Brand Tier 4. allergen extract) 2800 BAU sublingual tablets Inter-regional MPD Pharmacy and Therapeutics (im-pact) Committee February 4th, 2015 meeting 2015 National Medicare Part D Formulary Initial Tier Placement for Recently Launched and Approved Products Viekira Pak (ombitasvir, Placed on Specialty Tier 5; effective 1/1/2015. paritaprevir and ritonavir, copackaged with dasabuvir) tablets Lynparza (olaparib) 50 mg capsules Blincyto (blinatumomab) 35 mcg injection Opdivo (nivolumab) 40 mg/4 ml, 100 mg/10 ml injection Belsomra (suvorexant) 5 mg, 10 mg,15 mg, 20 mg tablets Trumenba (meningococcal group B) vaccine injection Lemtrada (alemtuzumab) 12 mg/1.2 ml injection Gardasil 9 (human papillomavirus 9-valent) vaccine, recombinant injection Savaysa (edoxaban) 15 mg, 30 mg, 60 mg tablets Impavido (miltefosine) 50 mg capsules Movantik (naloxegol) 12 mg, 15 mg tablets Vitekta (elvitegravir) 85 mg, 150 mg tablets Xtoro (finafloxacin) 0.30% suspension Protected Class. Placed on Specialty Tier 5; effective 1/1/2015. Protected Class. Placed on Specialty Tier 5; effective 1/1/2015. Protected Class. Placed on Specialty Tier 5; effective 1/1/2015. Placed on Non-Preferred Brand Tier 4; effective 2/3/2015. Placed on Part D Vaccine Tier 6; effective 2/3/2015. Placed on Specialty Tier 5; effective 2/3/2015. Placed on Part D Vaccine Tier 6; effective 2/3/2015. Placed on Non-Preferred Brand Tier 4; effective 2/3/2015. Placed on Non-Preferred Brand Tier 4; launch date pending. Placed on Non-Preferred Brand Tier 4; launch date pending. Protected Class. Placed on Specialty Tier 5 Pending; launch date pending. Placed on Non-Preferred Brand Tier 4 Pending; launch date pending.

11 Inter-regional MPD Pharmacy and Therapeutics (im-pact) Committee February 4th, 2015 meeting CMS/Medicare Part D Formulary Review: Formulary Decisions Based on Current/Ongoing Evaluations Farxiga (dapagliflozin) 5 mg, 10 mg tablets Vimizim (elosufase alfa) 5 mg/5ml injection Ragwitek (short ragweed pollen allergen extract) 12 AMB A 1-U sublingual tablets Oralair (sweet vernal, orchard, perennial rye, Timothy, and Kentucky Blue Grass mixed pollens allergen extract) 100 IR, 300 IR sublingual tablets Northera (droxidopa) 100 mg, 200 mg, 300 mg capsules Cerdelga (eliglustat) 84 mg capsules Kerydin (tavaborole) 5% topical solution Striverdi Respimat (olodaterol) 2.5 mcg/actuation aerosol solution, inhalation Plegridy (peginterferon beta-1a) prefilled 125 mcg/0.5 ml prefilled syringe, 63 mcg/0.5 ml and 95 mcg/0.5 ml Starter Pak Ofev (nintedanib) 100 mg, 150 mg capsules New drug approval as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Retained on Non- Preferred Brand Tier 4. New drug approval for the treatment of mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). Retained on Specialty Tier 5. New drug approval for the treatment of short ragweed pollen-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive skin test or in vitro testing for pollen- specific IgE antibodies for short ragweed pollen in adults 18 to 65 years of age. Retained on Non- Preferred Brand Tier 4. New drug approval for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for any of the 5 grass species contained in this product in patients 10 through 65 years of age. Retained on Non- Preferred Brand Tier 4. New drug approval for the treatment of orthostatic dizziness, lightheadedness, or the feeling that you are about to black out in adult patients with symptomatic neurogenic orthostatic hypotension (NOH) caused by primary autonomic failure (Parkinson disease [PD], multiple system atrophy [MSA], and pure autonomic failure [PAF]), dopamine beta-hydroxylase deficiency, and nondiabetic autonomic neuropathy. Specialist review in progress, remains on Specialty Tier 5. New drug approval for the treatment of adult patients with Gaucher disease type 1 (GD1) who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs). Specialist review in progress, remains on Specialty Tier 5. New drug approval for the treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes. Specialist review in progress, remains on Non-Preferred Brand Tier 4. New drug approval for the treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Specialist review in progress, remains on Non-Preferred Brand Tier 4. New drug approval for the treatment of patients with relapsing forms of multiple sclerosis. Specialist review in progress, remains on Specialty Tier 5. New drug approval for the treatment of idiopathic pulmonary fibrosis. Specialist review in progress, remains on Specialty Tier 5.

12 Inter-regional MPD Pharmacy and Therapeutics (im-pact) Committee February 4th, 2015 meeting CMS/Medicare Part D Formulary Review: Formulary Decisions Based on Current/Ongoing Evaluations cont d Orbactiv (oritavancin) 400 mg for intravenous injection Esbriet (pirfenidone) 267 mg capsules Humira (adalimumab) 20 mg/0.4 ml, 40 mg/0.8 ml Injection National Part D 30 Day Supply Drug List 2016 Calendar Year (CY) Formulary Initial Tiering File Opioid Retrospective Drug Utilization Review, Quarters 2, 3, 2014 Report Tybost (cobicistat) 150 mg tablet Jardiance (empagliflozin) 10 mg, 25 mg tablet Invokamet (canagliflozin/metformin) 50 mg/500 mg, 150 mg/500 mg, 50 mg/1000 mg, 150 mg/100 mg tablet Lemtrada (alemtuzumab) 12 mg/1.2 ml IV Akynzeo (netupitant and palonosetron) 300 mg /0.5 mg capsule New drug approval for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following gram- positive microorganisms: Staphylococcus aureus (including methicillinsusceptible and methicillin-resistant isolates); Streptococcus pyogenes; Streptococcus agalactiae; Streptococcus dysgalactiae, Streptococcus anginosus group (including S. anginosus, S. intermedius, S. constellatus); and Enterococcus faecalis (vancomycin- susceptible isolates only). Specialist review in progress, remains on Specialty Tier 5. New drug approval for the treatment of idiopathic pulmonary fibrosis. Specialist review in progress, remains on Specialty Tier 5 New indication for the treatment of childhood arthritis in younger patients. Retained on Specialty Tier 5. Inter-regional MPD Pharmacy and Therapeutics (im-pact) Committee February 4th, 2015 meeting Other Decisions Approved addition of the following drug(s) to the list: o Obredon (guaifenesin 200 mg/hydrocodone 2.5 mg/5 ml) oral solution o Viekira Pak (ombitasvir 12.5 mg, paritaprevir 75 mg and ritonavir 50 mg, co- packaged with dasabuvir 250 mg tablet) Approved Approved Effective dates reflect implementation into the systems. New Drugs and Indications Protected Class. Specialist review in progress, remains on Non- Preferred Brand Tier 4. Specialist review in progress, remains on Non- Preferred Brand Tier 4. Specialist review in progress, remains on Non- Preferred Brand Tier 4. Specialist review in progress, remains on Specialty Tier 5 Specialist review in progress, remains on Non- Preferred Brand Tier 4.

13 Tips on how to find formulary information from the computer KAISER PERMANENTE Mid-Atlantic States Region Pharmacy & Therapeutics Committee On the Kaiser Permanente Intranet 1. Where can I find the drug formulary online? Click on Formulary link on KP HealthConnect home page (bottom right), or MAPMG Providers via intranet: Go to Network Providers: Go to 2. How can I find out if something is on the drug formulary and view the drug monograph for a drug on the formulary? MAPMG Providers To view the criteria for use, contraindications, adverse reactions, drug interactions, and dosing information, click on the Lexi-comp Interactive Version under Full MAS Drug Formulary. When you enter the site, a search screen appears in the upper left hand corner of your screen. Type in the first few letters or the entire drug name and select SEARCH. All drugs containing that information are listed in the SEARCH RESULTS box. If a drug is not on formulary or it is spelled incorrectly, "No occurrences found" will appear in the SEARCH RESULTS box. Formulary status of a particular drug can be found in HealthConnect in the Pharmacy column in the drug listing. Yes in this column means that particular product is formulary. Remember, there are sometimes many duplicative products for a single drug entity. In that event, scroll down the list to look for the product that is formulary. Network Providers Go to Click on comprehensive listing of formulary drugs Press (ctrl+f) and search for the particular drug of interest on the Find field appearing on the upper left corner of the screen. If the drug is spelled incorrectly or is not on the formulary the following message will appear The Item was not found 3. How can I receive a copy of the formulary? MAPMG Providers Go to You may print a copy of the formulary document Network Providers Go to Click on comprehensive listing of formulary drugs You may print a copy of the formulary document You may also contact our Provider Relations Department at for a paper copy of our formularies.

14 4. How can I request an addition or deletion from the formulary? New drug entities remain Non-formulary until reviewed by the Regional P&T Committee. We will review any drug upon written request with supporting evidence to make an evidence-based decision. The Drug Formulary Addition and Deletion Request Form can be obtained via the internet for both MAPMG and Network Providers: MAPMG: Go to RequestForm.pdf Network Providers: Go to Under section Request to review medications for addition/deletion to the formulary, click on download a form. The completed form can be 1. Faxed at , attention: P&T Committee co-chairs 2. Mailed to: Kaiser Permanente Regional Office, Pharmacy 3-West Attention: P&T Committee Co-Chairs, Drug Review 2101 East Jefferson Street Rockville, MD ed by contacting any of the P&T Committee Co-Chairs: Carol Forster, MD Sheireen Huang, PharmD Ashely Kim, PharmD

15 FORMULARY REVIEW PROCESS Applying evidence-based medicine, the Regional P&T Committee and its Consultants determine whether a medicine should be added to the drug formulary. The key points of this evidencebased review are highlighted; a full description of the formulary review process is available at: Non-formulary Medication Exception Process: Developed to provide access to medically necessary drugs under a member s drug benefit even when that drug is not on the Formulary. Ensures the practitioner makes the final decision regarding what drug is appropriate for the member. Non-formulary drugs should be used only if the member fails to respond to formulary drug therapy, or has special circumstances requiring the use of a non-formulary drug. Non-formulary Exception Reason: o Allergy/Adverse reaction to formulary drug(s) o Treatment failure to formulary drug(s) o Meets specific criteria/restriction according to Kaiser Permanente drug treatment guidelines. o Formulary alternatives available/patient request non-covered, non-formulary drug the patient will pay full Member Rate price. *Stewardship: We ensure our stewardship by using and managing our resources appropriately - KPMAS Applying evidence-based medicine, the Regional Pharmacy and Therapeutics Committee and its Consultants determine whether a medicine should be added to the drug formulary. The key points of this evidence-based review are highlighted; a full description of the formulary review process is available at: mularyprocessguide.pdf CONFIDENTIAL FOR INTERNAL USE ONLY